New direct thrombin inhibitors
- 189 Downloads
Direct thrombin inhibitors (DTIs) are a class of anticoagulants that bind selectively to thrombin and block its interaction with its substrates. Dabigatran etexilate and AZD0837, the new generation of DTIs, are now under intense development, and are potentially of great interest for internists. Dabigatran etexilate is a potent, non-peptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of thrombin molecule. It has been already licensed in the European Union and in Canada for the prevention of VTE in patients undergoing hip- and knee-replacement surgery. Ongoing trials are evaluating its efficacy and safety for the treatment of deep venous thrombosis and pulmonary embolism, primary and secondary prevention of VTE, prevention of systemic embolism in patients with non-valvular atrial fibrillation, and prevention of cardiac events in patients with acute coronary syndromes. AZD0837 is the prodrug of ARH06737, a potent, competitive, reversible inhibitor of free and fibrin-bound thrombin. At present, only limited, preclinical, phase I and phase II clinical data have been presented. The drug has now entered a phase III clinical program in the population of patients with atrial fibrillation. Their properties and the oral administration render these compounds, theoretically, more convenient than both vitamin K antagonist and low molecular weight heparins. However, only reports from clinical practice patterns over the next months and years will tell us how and when to use the new DTIs.
KeywordsAnticoagulants Thrombin inhibitors Dabigatran Venous thromboembolism Atrial fibrillation
The authors did not receive any financial support to write this manuscript.
Conflict of interest statement
The authors declare that they have no conflict of interest related to the publication of this manuscript.
- 4.European Medicines Agency (EMEA). European public assessment report: Pradaxa [online]. Available at URL:http://www.emea.europa.eu
- 6.Mungall D (2002) BIBR-1048 Boehringer Ingelheim. Curr Opin Invest Drugs 3:905–907Google Scholar
- 13.RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA (2009) The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2:1–9Google Scholar
- 15.Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L (2007) Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 100:1419–1426CrossRefPubMedGoogle Scholar
- 17.Lip GYH et al (2009) The oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with atrial fibrillation: a phase II randomized dose-guiding, safety and tolerability study. Abstract 1021 presented at the 58th Annual Scientific Sessions of the American College of Cardiology (ACC), in Orlando, Florida, 29–31 March 2009Google Scholar
- 18.Cullberg M, Eriksson U, Wernevik L et al (2007) Effect of ketoconazole and grapefruit juice on the pharmacokinetics of the oral direct thrombin inhibitor AZD0837 [abstract n. 205]. Basic Clin Pharmacol Toxicol 101:130Google Scholar